Visit www.PfizerRxPathways.com. xref 0000040517 00000 n 0000031219 00000 n Pfizer Inc may use this information to contact you and to provide the services you request.For information on data collection and use, please read our full corporate Privacy Policy (), which is incorporated by reference into these Terms.Pfizer Inc will not be liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator.This Program is available only on these US participating mobile carriers: Verizon Wireless, Sprint, Boost Mobile, T-Mobile, AT&T, Atlantic Tele-Network International (ATNI), Alaska Communications Systems (ACS), ASTAC, Bandwidth.com (includes Republic Wireless), Blue Wireless, Bluegrass Cellular, Breakaway Wireless, Brightlink, C Spire Wireless (aka Cellular South), Carolina West Wireless, CellCom, Cellone Nation, Cellular One of N.E. You may notify Pfizer Inc of a number change by calling 1-844-935-5269.Message and data rates may apply to each text message sent or received in connection with the texting program, as provided in your mobile telephone service rate plan (please contact your mobile telephone carrier for pricing plans). Patients should be tested for latent tuberculosis before XELJANZ/XELJANZ XR use and during therapy.

0000031804 00000 n Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

0000073122 00000 n You can also call customer service at 1-844-935-5269.You represent that you are the account holder for the mobile telephone number(s) that you provide to opt into the Program. See 22 mg once daily for at least 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. 0000049730 00000 n

0000034379 00000 n The most commonly reported adverse reactions during the first 3 months in controlled clinical trials in patients with RA with XELJANZ 5 mg twice daily and placebo, respectively, (occurring in greater than or equal to 2% of patients treated with XELJANZ with or without DMARDs) were upper respiratory tract infection, nasopharyngitis, diarrhea, headache, and hypertension. 0000032967 00000 n 0000032154 00000 n

After a maximum of $15,000, you will be responsible for paying the remaining monthly out-of-pocket costs.This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.You must deduct the value of this card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.You are responsible for reporting use of the Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required. If needed, continue 22 mg once daily for a maximum of 16 weeks. In the UC population, treatment with XELJANZ 10 mg twice daily was associated with greater risk of NMSC. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Card redemptions and will not identify you.Pfizer reserves the right to rescind, revoke, or amend the program without notice.If you have questions or are in need of additional support, call 1-844-935-5269 or visit Interim Care Rx is not health insurance and is available for eligible, commercially insured patients only.Offer is only available to patients who have been diagnosed with an FDA-approved indication for XELJANZ/XELJANZ XR.No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer.Not available to patients covered under government plans such as Medicaid, Medicare or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio, or Rhode Island.Available in 30-day supply. 0000036049 00000 n 0000000016 00000 n for the Pfizer RxPathways™® for XELJANZ Program. In these studies, many patients with rheumatoid arthritis were receiving background therapy with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). 0000047997 00000 n The most commonly reported adverse reactions during the first 3 months in controlled clinical trials in patients with RA with XELJANZ 5 mg twice daily and placebo, respectively, (occurring in greater than or equal to 2% of patients treated with XELJANZ with or without DMARDs) were upper respiratory tract infection, nasopharyngitis, diarrhea, headache, and hypertension. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Card redemptions and will not identify you.Pfizer reserves the right to rescind, revoke, or amend the program without notice.If you have questions or are in need of additional support call 1-844-935-5269 or visit By opting into the XSAVINGS mobile texting program (Program), you consent to receive up to 10 text messages and/or push notifications from Pfizer Inc. TrialCard, carriers (including, but not limited to, T-Mobile) and any service providers utilized by TrialCard to send messages are not liable for delayed or undelivered messages.To stop receiving text messages, text STOP to 50336. 0000027962 00000 n 310 148 0000065424 00000 n 0000071777 00000 n

The support provided through this program is not contingent on any future purchase. 0000035613 00000 n Update immunizations in agreement with current immunization guidelines prior to initiating XELJANZ/XELJANZ XR therapy.Caution should be used when administering XELJANZ XR to patients with pre-existing severe gastrointestinal narrowing. 0000042367 00000 n 0000005472 00000 n